Boehringer Ingelheim Press Releases This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

Boehringer Ingelheim Welcomes Central Role of LAMA/LABA Therapy within 2017 GOLD Strategy for COPD
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 16, 2016 Category: Research Source Type: news

Boehringer Ingelheim bevacizumab biosimilar candidate demonstrates bioequivalence to Avastin ®
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 15, 2016 Category: Research Source Type: news

Updated Phase III Results Reinforce Safety and Efficacy of Praxbind ® (idarucizumab) in Urgent Situations
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 14, 2016 Category: Research Source Type: news

First Data from Boehringer Ingelheim, Anthem and HealthCore Multi-Year Study Show Gaps in Non-valvular Atrial Fibrillation Care
Findings from more than 45,000 NVAF patients show less than half were treated with an oral anticoagulant, including those at highest risk of stroke Data presented at American Heart Association Scientific Sessions will be used to guide future research to help improve patient outcomes (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 13, 2016 Category: Research Source Type: news

Jardiance ® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 12, 2016 Category: Research Source Type: news

Boehringer Ingelheim Named One of Science Magazine ’s Top Employers for the Twelfth Consecutive Year
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 26, 2016 Category: Research Source Type: news

Boehringer Ingelheim ’s adalimumab biosimilar candidate shows similar efficacy and safety profile to Humira® in pivotal Phase III study
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 25, 2016 Category: Research Source Type: news

Efficacy of Ofev ® (nintedanib) Reinforced in Range of Patients with IPF in New Analyses Presented at CHEST
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 23, 2016 Category: Research Source Type: news

New Real-World Data Show Pradaxa ® (dabigatran etexilate mesylate) Treatment Resulted in Less Use of All-Cause Healthcare Resources than Warfarin Treatment
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 20, 2016 Category: Research Source Type: news

Boehringer Ingelheim joins The Leukemia & Lymphoma Society in groundbreaking precision medicine approach to treating acute myeloid leukemia
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 17, 2016 Category: Research Source Type: news

New Data Analyses Provide Insights That May Help Predict COPD Exacerbation Risk
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 16, 2016 Category: Research Source Type: news

New Support Program Provides Free Medicine and Resources for People Living with COPD Prescribed STIOLTO ® RESPIMAT® (tiotropium bromide and olodaterol) Inhalation Spray
“STIOLTO Promise” Program Includes Free 30-Days of Medicine and At-Home Counsel from Respiratory Therapist or Nurse (Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 11, 2016 Category: Research Source Type: news

Phase III nintedanib trial results in patients with metastatic colorectal cancer announced at ESMO
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 8, 2016 Category: Research Source Type: news

Overall survival data from LUX-Lung 7 head-to-head trial of Gilotrif ® (afatinib) versus Iressa® (gefitinib) presented at ESMO
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 8, 2016 Category: Research Source Type: news

Researchers Publish Largest Observational Study To-Date Comparing Novel Oral Anticoagulants (NOACs) Pradaxa ® (dabigatran etexilate mesylate) and Rivaroxaban
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - October 5, 2016 Category: Research Source Type: news